{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["ABCG2", "EGCG", "drug interaction", "green tea", "rosuvastatin", "soy isoflavones"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35399656", "DateRevised": {"Year": "2022", "Month": "04", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "03", "Day": "24"}], "Language": ["eng"], "ELocationID": ["850318", "10.3389/fnut.2022.850318"], "Journal": {"ISSN": "2296-861X", "JournalIssue": {"Volume": "9", "PubDate": {"Year": "2022"}}, "Title": "Frontiers in nutrition", "ISOAbbreviation": "Front Nutr"}, "ArticleTitle": "Effect of Green Tea Extract and Soy Isoflavones on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers.", "Pagination": {"StartPage": "850318", "MedlinePgn": "850318"}, "Abstract": {"AbstractText": ["Green tea and soy products are extensively consumed in daily life. Research has shown that green tea catechins and soy isoflavones may influence the activity of drug metabolizing enzymes and drug transporters. We examined whether regular consumption of green tea extract or soy isoflavones affected the pharmacokinetics of a single dose of rosuvastatin in healthy subjects and whether any interactions were influenced by the polymorphism in the drug transporter ABCG2.", "This was an open-label, three-phase randomized crossover study with single doses of rosuvastatin.", "Healthy Chinese male subjects were given a single dose of rosuvastatin 10 mg on 3 occasions: 1. without herbs; 2. with green tea extract; 3. with soy isoflavone extract. The green tea and soy isoflavone extract were given at a dose containing EGCG 800 mg once daily or soy isoflavones-80 mg once daily for 14 days before statin dosing and at the same time as the statin dosing with at least 4-weeks washout period between phases.", "Twenty healthy male subjects completed the study and the intake of green tea extract significantly reduced the systemic exposure to rosuvastatin by about 20% reducing AUC<sub>0-24<i>h</i></sub> from [geometric mean (% coefficient of variation)] 108.7 (28.9) h\u00b7\u03bcg/L to 74.1 (35.3) h\u00b7\u03bcg/L and C<sub>max</sub> from 13.1 (32.2) \u03bcg/L to 7.9 (38.3) \u03bcg/L (<i>P</i> < 0.001 for both), without affecting the elimination half-life. The ABCG2 421C>A polymorphism had a significant effect on rosuvastatin exposure but no impact on the interaction with green tea. Soy isoflavones had no significant effect on rosuvastatin pharmacokinetics.", "This study showed that repeated administration of green tea extract significantly reduced the systemic exposure of rosuvastatin in healthy volunteers. These effects might be predicted to either reduce or increase the lipid-lowering effect of rosuvastatin depending on the mechanism of the effect."], "CopyrightInformation": "Copyright \u00a9 2022 Zeng, Hu, Lee, Wat, Lau, Ho, Wong and Tomlinson."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shenzhen Baoan Women's and Children's Hospital, Jinan University, Shenzhen, China."}], "LastName": "Zeng", "ForeName": "Weiwei", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong SAR, China."}], "LastName": "Hu", "ForeName": "Miao", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China."}, {"Identifier": [], "Affiliation": "Department of Clinical Pathology, Tuen Mun Hospital, Hong Kong, Hong Kong SAR, China."}], "LastName": "Lee", "ForeName": "Hon Kit", "Initials": "HK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China."}], "LastName": "Wat", "ForeName": "Elaine", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China."}], "LastName": "Lau", "ForeName": "Clara Bik San", "Initials": "CBS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China."}], "LastName": "Ho", "ForeName": "Chung Shun", "Initials": "CS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China."}, {"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China."}], "LastName": "Wong", "ForeName": "Chun Kwok", "Initials": "CK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong SAR, China."}, {"Identifier": [], "Affiliation": "Faculty of Medicine, Macau University of Science and Technology, Macau, China."}], "LastName": "Tomlinson", "ForeName": "Brian", "Initials": "B"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Nutr", "NlmUniqueID": "101642264", "ISSNLinking": "2296-861X"}, "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Khan J, Deb PK, Priya S, Medina KD, Devi R, Walode SG et al. Dietary flavonoids: cardioprotective potential with antioxidant effects and their pharmacokinetic, toxicological and therapeutic concerns. Molecules. (2021) 26:4021. 10.3390/molecules26134021", "ArticleIdList": ["10.3390/molecules26134021", "PMC8272101", "34209338"]}, {"Citation": "Liperoti R, Vetrano DL, Bernabei R, Onder G. Herbal medications in cardiovascular medicine. J Am Coll Cardiol. (2017) 69:1188\u20131199. 10.1016/j.jacc.2016.11.078", "ArticleIdList": ["10.1016/j.jacc.2016.11.078", "28254182"]}, {"Citation": "Shaito A, Thuan DTB, Phu HT, Nguyen THD, Hasan H, Halabi S et al. Herbal medicine for cardiovascular diseases: efficacy, mechanisms, and safety. Front Pharmacol. (2020) 11:422. 10.3389/fphar.2020.00422", "ArticleIdList": ["10.3389/fphar.2020.00422", "PMC7155419", "32317975"]}, {"Citation": "Tomlinson B, Hu M, Lee VW. In vivo assessment of herb-drug interactions: possible utility of a pharmacogenetic approach? Mol Nutri Food Res. (2008) 52:799\u2013809. 10.1002/mnfr.200700454", "ArticleIdList": ["10.1002/mnfr.200700454", "18618477"]}, {"Citation": "Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics. (2004) 14:841\u201350. 10.1097/00008571-200412000-00007", "ArticleIdList": ["10.1097/00008571-200412000-00007", "15608563"]}, {"Citation": "Ronis MJJ. Effects of soy containing diet and isoflavones on cytochrome P450 enzyme expression and activity. Drug Metabol Rev. (2016) 48:331\u201341. 10.1080/03602532.2016.1206562", "ArticleIdList": ["10.1080/03602532.2016.1206562", "PMC5801744", "27440109"]}, {"Citation": "Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK et al. Statin-associated muscle symptoms: impact on statin therapy-european atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J. (2015) 36:1012\u201322. 10.1093/eurheartj/ehv043", "ArticleIdList": ["10.1093/eurheartj/ehv043", "PMC4416140", "25694464"]}, {"Citation": "Turner RM, Pirmohamed M. Statin-Related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med. (2019) 9:10022 10.3390/jcm9010022", "ArticleIdList": ["10.3390/jcm9010022", "PMC7019839", "31861911"]}, {"Citation": "Zeng W, Tomlinson B. Causes and outcome of rhabdomyolysis in patients admitted to medical wards in the prince of wales hospital. Ann Transl Med. (2021) 9:1329. 10.21037/atm-21-3660", "ArticleIdList": ["10.21037/atm-21-3660", "PMC8422091", "34532466"]}, {"Citation": "Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB et al. Statin safety and associated adverse events: a scientific statement from the american heart association. Arterioscler Thromb Vasc Biol. (2019) 39:e38\u2013e81. 10.1161/ATV.0000000000000073", "ArticleIdList": ["10.1161/ATV.0000000000000073", "30580575"]}, {"Citation": "Xiang Q, Chen S-q, Ma L-y, Hu K, Zhang Z, Mu G-y et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenom J. (2018) 18:721\u20139. 10.1038/s41397-018-0054-0", "ArticleIdList": ["10.1038/s41397-018-0054-0", "30250148"]}, {"Citation": "Nikolic D, Banach M, Chianetta R, Luzzu LM, Pantea Stoian A, Diaconu CC et al. An overview of statin-induced myopathy and perspectives for the future. Expert Opinion Drug Safety. (2020) 19:601\u201315. 10.1080/14740338.2020.1747431", "ArticleIdList": ["10.1080/14740338.2020.1747431", "32233708"]}, {"Citation": "Liu J-E, Liu X-Y, Chen S, Zhang Y, Cai L-Y, Yang M et al. SLCO1B1 521T> C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case\u2013control study. Euro J Clinic Pharmacol. (2017) 73:1409\u201316. 10.1007/s00228-017-2318-z", "ArticleIdList": ["10.1007/s00228-017-2318-z", "28812116"]}, {"Citation": "Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F et al. SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study. New Engl J Med. (2008) 359:789\u201399. 10.1056/NEJMoa0801936", "ArticleIdList": ["10.1056/NEJMoa0801936", "18650507"]}, {"Citation": "Hu M, Lee MH, Mak VW, Tomlinson B. Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily). Am J Cardiol. (2010) 106:1588\u201393. 10.1016/j.amjcard.2010.07.044", "ArticleIdList": ["10.1016/j.amjcard.2010.07.044", "21094359"]}, {"Citation": "Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. (2010) 87:558\u201362. 10.1038/clpt.2009.232", "ArticleIdList": ["10.1038/clpt.2009.232", "20130569"]}, {"Citation": "Carr DF, Francis B, Jorgensen AL, Zhang E, Chinoy H, Heckbert SR et al. Genomewide association study of statin-induced myopathy in patients recruited using the UK clinical practice research datalink. Clinic Pharmacol Therapeutics. (2019) 106:1353\u201361. 10.1002/cpt.1557", "ArticleIdList": ["10.1002/cpt.1557", "PMC6896237", "31220337"]}, {"Citation": "Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. (2006) 130:1793\u2013806. 10.1053/j.gastro.2006.02.034", "ArticleIdList": ["10.1053/j.gastro.2006.02.034", "16697742"]}, {"Citation": "Windass AS, Lowes S, Wang Y, Brown CD. The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. (2007) 322:1221\u20137. 10.1124/jpet.107.125831", "ArticleIdList": ["10.1124/jpet.107.125831", "17585018"]}, {"Citation": "Rouhi-Boroujeni H, Rouhi-Boroujeni H, Heidarian E, Mohammadizadeh F, Rafieian-Kopaei M. Herbs with anti-lipid effects and their interactions with statins as a chemical anti-hyperlipidemia group drugs: a systematic review. ARYA atherosclerosis. (2015) 11:244.", "ArticleIdList": ["PMC4593660", "26478732"]}, {"Citation": "Werba JP, Giroli M, Cavalca V, Nava MC, Tremoli E, Dal Bo L. The effect of green tea on simvastatin tolerability. Ann Intern Med. (2008) 149:286\u2013287. 10.7326/0003-4819-149-4-200808190-00019", "ArticleIdList": ["10.7326/0003-4819-149-4-200808190-00019", "18711168"]}, {"Citation": "Alvarez AI, Real R, P\u00e9rez M, Mendoza G, Prieto JG, Merino G. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J Pharmaceutic Sci. (2010) 99:598\u2013617. 10.1002/jps.21851", "ArticleIdList": ["10.1002/jps.21851", "19544374"]}, {"Citation": "Xiang Y, Liu S, Yang J, Wang Z, Zhang H, Gui C. Investigation of the interactions between flavonoids and human organic anion transporting polypeptide 1B1 using fluorescent substrate and 3D-QSAR analysis. Biochimica et Biophysica Acta (BBA)-Biomembranes. (2020) 1862:183210. 10.1016/j.bbamem.2020.183210", "ArticleIdList": ["10.1016/j.bbamem.2020.183210", "32006472"]}, {"Citation": "Lee VW, Chau TS, Leung VP, Lee KK, Tomlinson B. Clinical efficacy of rosuvastatin in lipid management in Chinese patients in Hong Kong. Chin Med J (Engl). (2009) 122:2814\u20132819. 10.3760/cma.j.issn.0366-6999.2009.23.003", "ArticleIdList": ["10.3760/cma.j.issn.0366-6999.2009.23.003", "20092783"]}, {"Citation": "Eng QY, Thanikachalam PV, Ramamurthy S. Molecular understanding of Epigallocatechin gallate (EGCG) in cardiovascular and metabolic diseases. J Ethnopharmacol. (2018) 210:296\u2013310. 10.1016/j.jep.2017.08.035", "ArticleIdList": ["10.1016/j.jep.2017.08.035", "28864169"]}, {"Citation": "Setchell KD. Soy isoflavones\u2013benefits and risks from nature's selective estrogen receptor modulators (SERMs). J Am Coll Nutr. (2001) 20:354S\u2212362S. 10.1080/07315724.2001.10719168", "ArticleIdList": ["10.1080/07315724.2001.10719168", "11603644"]}, {"Citation": "Xiao Y, Zhang S, Tong H, Shi S. Comprehensive evaluation of the role of soy and isoflavone supplementation in humans and animals over the past two decades. Phytotherapy Res. (2018) 32:384\u201394. 10.1002/ptr.5966", "ArticleIdList": ["10.1002/ptr.5966", "29193539"]}, {"Citation": "Lee HK, Ho CS, Hu M, Tomlinson B, Wong CK. Development and validation of a sensitive method for simultaneous determination of rosuvastatin and N-desmethyl rosuvastatin in human plasma using liquid chromatography/negative electrospray ionization/tandem mass spectrometry. Biomed Chromatogr. (2013) 3:2944. 10.1002/bmc.2944", "ArticleIdList": ["10.1002/bmc.2944", "23722358"]}, {"Citation": "Fan L, Zhang W, Guo D, Tan ZR, Xu P, Li Q et al. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther. (2008) 83:471\u20136. 10.1038/sj.clpt.6100318", "ArticleIdList": ["10.1038/sj.clpt.6100318", "17851565"]}, {"Citation": "Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. (2011) 82:1807\u201321. 10.1016/j.bcp.2011.07.093", "ArticleIdList": ["10.1016/j.bcp.2011.07.093", "PMC4082721", "21827739"]}, {"Citation": "Koutelidakis AE, Rallidis L, Koniari K, Panagiotakos D, Komaitis M, Zampelas A et al. Effect of green tea on postprandial antioxidant capacity, serum lipids, C-reactive protein and glucose levels in patients with coronary artery disease. Eur J Nutr. (2013) 13:548. 10.1007/s00394-013-0548-0", "ArticleIdList": ["10.1007/s00394-013-0548-0", "23793133"]}, {"Citation": "Suliburska J, Bogdanski P, Szulinska M, Stepien M, Pupek-Musialik D, Jablecka A. Effects of green tea supplementation on elements, total antioxidants, lipids, and glucose values in the serum of obese patients. Biol Trace Elem Res. (2012) 149:315\u201322. 10.1007/s12011-012-9448-z", "ArticleIdList": ["10.1007/s12011-012-9448-z", "PMC3501173", "22581111"]}, {"Citation": "Basu A, Sanchez K, Leyva MJ, Wu M, Betts NM, Aston CE et al. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. J Am Coll Nutr. (2010) 29:31\u201340. 10.1080/07315724.2010.10719814", "ArticleIdList": ["10.1080/07315724.2010.10719814", "20595643"]}, {"Citation": "Yang CS, Pan E. The effects of green tea polyphenols on drug metabolism. Expert Opin Drug Metab Toxicol. (2012) 8:677\u201389. 10.1517/17425255.2012.681375", "ArticleIdList": ["10.1517/17425255.2012.681375", "22509899"]}, {"Citation": "Yang SP, Raner GM. Cytochrome P450 expression and activities in human tongue cells and their modulation by green tea extract. Toxicol Appl Pharmacol. (2005) 202:140\u201350. 10.1016/j.taap.2004.06.014", "ArticleIdList": ["10.1016/j.taap.2004.06.014", "15629189"]}, {"Citation": "Yao HT, Hsu YR, Lii CK, Lin AH, Chang KH, Yang HT. Effect of commercially available green and black tea beverages on drug-metabolizing enzymes and oxidative stress in Wistar rats. Food Chem Toxicol. (2014) 70:120\u20137. 10.1016/j.fct.2014.04.043", "ArticleIdList": ["10.1016/j.fct.2014.04.043", "24815822"]}, {"Citation": "Farabegoli F, Papi A, Bartolini G, Ostan R, Orlandi M. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine. (2010) 17:356\u201362. 10.1016/j.phymed.2010.01.001", "ArticleIdList": ["10.1016/j.phymed.2010.01.001", "20149610"]}, {"Citation": "Roth M, Timmermann BN, Hagenbuch B. Interactions of green tea catechins with organic anion-transporting polypeptides. Drug Metab Dispos. (2011) 39:920\u20136. 10.1124/dmd.110.036640", "ArticleIdList": ["10.1124/dmd.110.036640", "PMC3082372", "21278283"]}, {"Citation": "Yue M, Yang J, Jin M, Steiert B, Xiang Y, Zhang H et al. Gly45 and Phe555 in transmembrane domains 1 and 10 are critical for the activation of organic anion transporting polypeptide 1b3 by epigallocatechin gallate. J Agric Food Chem. (2019) 67:9079\u201387. 10.1021/acs.jafc.9b03812", "ArticleIdList": ["10.1021/acs.jafc.9b03812", "PMC6892160", "31353905"]}, {"Citation": "Zamek-Gliszczynski MJ, Patel M, Yang X, Lutz JD, Chu X, Brouwer KLR et al. Intestinal P-gp and Putative Hepatic OATP1B induction: international transporter consortium perspective on drug development implications. Clin Pharmacol Ther. (2021) 109:55\u201364. 10.1002/cpt.1916", "ArticleIdList": ["10.1002/cpt.1916", "PMC8020731", "32460379"]}, {"Citation": "Kim TE, Ha N, Kim Y, Kim H, Lee JW, Jeon JY et al. Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers. Drug Des Devel Ther. (2017) 11:1409\u201316. 10.2147/DDDT.S130050", "ArticleIdList": ["10.2147/DDDT.S130050", "PMC5431696", "28533679"]}, {"Citation": "Hu M, Tomlinson B. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. Expert Opin Drug Metab Toxicol. (2014) 10:51\u201365. 10.1517/17425255.2014.851667", "ArticleIdList": ["10.1517/17425255.2014.851667", "24156555"]}, {"Citation": "Lee HK, Hu M, Lui S, Ho CS, Wong CK, Tomlinson B. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. (2013) 14:1283\u201394. 10.2217/pgs.13.115", "ArticleIdList": ["10.2217/pgs.13.115", "23930675"]}, {"Citation": "Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet. (2012) 5:257\u201364. 10.1161/CIRCGENETICS.111.961144", "ArticleIdList": ["10.1161/CIRCGENETICS.111.961144", "22331829"]}, {"Citation": "Kim Y, Yoon S, Choi Y, Yoon SH, Cho JY, Jang IJ et al. Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects. Sci Rep. (2019) 9:19410. 10.1038/s41598-019-55562-4", "ArticleIdList": ["10.1038/s41598-019-55562-4", "PMC6923423", "31857620"]}, {"Citation": "Fleisher B, Unum J, Shao J, An G. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction. J Pharm Sci. (2015) 104:266\u201375. 10.1002/jps.24289", "ArticleIdList": ["10.1002/jps.24289", "25418056"]}, {"Citation": "Misaka S, Miyazaki N, Fukushima T, Yamada S, Kimura J. Effects of green tea extract and (-)-epigallocatechin-3-gallate on pharmacokinetics of nadolol in rats. Phytomedicine. (2013) 20:1247\u20131250. 10.1016/j.phymed.2013.07.003", "ArticleIdList": ["10.1016/j.phymed.2013.07.003", "23920278"]}, {"Citation": "Misaka S, Yatabe J, Muller F, Takano K, Kawabe K, Glaeser H et al. Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. Clin Pharmacol Ther. (2014) 95:432\u20138. 10.1038/clpt.2013.241", "ArticleIdList": ["10.1038/clpt.2013.241", "24419562"]}, {"Citation": "Ge J, Tan BX, Chen Y, Yang L, Peng XC, Li HZ et al. Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability. J Mol Med (Berl). (2011) 89:595\u2013602. 10.1007/s00109-011-0737-3", "ArticleIdList": ["10.1007/s00109-011-0737-3", "21331509"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "1", "Day": "7"}, {"Year": "2022", "Month": "2", "Day": "9"}, {"Year": "2022", "Month": "4", "Day": "11", "Hour": "5", "Minute": "16"}, {"Year": "2022", "Month": "4", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "4", "Day": "12", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["35399656", "PMC8987933", "10.3389/fnut.2022.850318"]}}], "PubmedBookArticle": []}